NASDAQ : RGC
Regencell Bioscience Holdings Limited — Financial statements
Healthcare · Drug Manufacturers - Specialty & Generic · Hong Kong
Last price 6.71 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.33B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 10.42M | 10.42M | 2.82M | 3.67M | 4.69M | 5.11M |
| Research & Development | 1.30M | 1.30M | 948.29K | 1.07M | 1.58M | 2.51M |
| Operating Expenses | 11.72M | 11.72M | 3.77M | 4.74M | 6.27M | 7.62M |
| Operating Income | -11.72M | -11.72M | -3.77M | -4.74M | -6.27M | -7.62M |
| EBT Excluding Unusual Items | -11.72M | -11.72M | -3.77M | -4.74M | -6.27M | -7.62M |
| Other Unusual Items | 22.52K | 22.52K | 185.77K | 373.50K | 211.34K | 23.21K |
| Pretax Income | -11.70M | -11.70M | -3.58M | -4.36M | -6.06M | -7.59M |
| Earnings From Continuing Operations | -11.70M | -11.70M | -3.58M | -4.36M | -6.06M | -7.59M |
| Minority Interest in Earnings | 61.38K | 191.20K | 148.61K | |||
| Net Income | -11.70M | -11.70M | -3.58M | -4.30M | -5.87M | -7.45M |
| Net Income to Common | -11.70M | -11.70M | -3.58M | -4.30M | -5.87M | -7.45M |
| Shares Outstanding (Basic) | 494.60M | 494.60M | 494.49M | 494.49M | 494.49M | 486.62M |
| Shares Outstanding (Diluted) | 494.60M | 494.60M | 494.49M | 494.49M | 494.49M | 486.62M |
| EPS (Basic) | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| EPS (Diluted) | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 |
| Free Cash Flow | -7.70M | -7.70M | -3.27M | -4.01M | -4.99M | -6.05M |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| EBITDA | -11.64M | -11.64M | -3.69M | -4.43M | -5.98M | -7.47M |
| D&A For EBITDA | 80.91K | 80.91K | 77.69K | 305.78K | 293.13K | 150.15K |
| EBIT | -11.72M | -11.72M | -3.77M | -4.74M | -6.27M | -7.62M |
| Advertising Expenses | 1.00K | 30.00K | 30.00K |
Balance sheet
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 14.19M | 14.19M | 2.42M | 2.96M | 1.56M | 6.42M |
| Short-Term Investments | 2.48M | 5.00M | 10.00M | 10.00M | ||
| Cash & Short-Term Investments | 14.19M | 14.19M | 4.90M | 7.96M | 11.56M | 16.42M |
| Prepaid Expenses | 30.70K | 30.70K | 5.80K | 152.78K | 56.55K | 27.60K |
| Total Current Assets | 14.22M | 14.22M | 4.90M | 8.11M | 11.62M | 16.44M |
| Property, Plant & Equipment | 430.73K | 430.73K | 759.82K | 226.51K | 891.91K | 1.46M |
| Other Long-Term Assets | 75.67K | 75.67K | 92.95K | 97.68K | 108.50K | 114.30K |
| Total Assets | 14.73M | 14.73M | 5.76M | 8.44M | 12.62M | 18.02M |
| Accrued Expenses | 1.07M | 1.07M | 348.35K | 125.33K | 158.08K | 151.13K |
| Current Portion of Leases | 236.31K | 236.31K | 312.78K | 59.81K | 438.26K | 410.99K |
| Other Current Liabilities | 10.79K | 10.79K | 2.54K | 8.44K | 10.57K | 15.65K |
| Total Current Liabilities | 1.32M | 1.32M | 663.67K | 193.58K | 606.91K | 577.76K |
| Long-Term Leases | 59.50K | 59.50K | 231.63K | 25.93K | 25.41K | 360.27K |
| Total Liabilities | 1.38M | 1.38M | 895.31K | 219.51K | 632.32K | 938.03K |
| Common Stock | 4.96K | 4.96K | 4.95K | 130.00 | 130.00 | 130.00 |
| Additional Paid-In Capital | 50.29M | 50.29M | 30.12M | 29.88M | 29.43M | 28.51M |
| Retained Earnings | -36.90M | -36.90M | -25.20M | -21.62M | -17.32M | -11.44M |
| Comprehensive Income & Other | -45.26K | -45.26K | -64.79K | -45.77K | -86.66K | |
| Total Common Equity | 13.35M | 13.35M | 4.86M | 8.22M | 12.03M | 17.07M |
| Minority Interest | -40.90K | 15.39K | ||||
| Shareholders' Equity | 13.35M | 13.35M | 4.86M | 8.22M | 11.99M | 17.08M |
| Total Liabilities & Equity | 14.73M | 14.73M | 5.76M | 8.44M | 12.62M | 18.02M |
| Total Debt | 295.81K | 295.81K | 544.41K | 85.74K | 463.67K | 771.25K |
| Net Cash (Debt) | 13.90M | 13.90M | 4.35M | 7.88M | 11.10M | 15.65M |
| Net Cash Per Share | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | 0.03 |
| Filing Date Shares Outstanding | 495.88M | 495.88M | 494.49M | 494.49M | 494.49M | 494.49M |
| Total Common Shares Outstanding | 495.88M | 495.88M | 494.49M | 494.49M | 494.49M | 494.49M |
| Working Capital | 12.90M | 12.90M | 4.24M | 7.92M | 11.01M | 15.87M |
| Book Value Per Share | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | 0.03 |
| Tangible Book Value | 13.35M | 13.35M | 4.86M | 8.22M | 12.03M | 17.07M |
| Tangible Book Value Per Share | 0.03 | 0.03 | 0.01 | 0.02 | 0.02 | 0.03 |
| Machinery | 452.65K | 452.65K | 452.08K | 302.10K | 295.58K | 297.19K |
| Leasehold Improvements | 621.42K | 621.42K | 620.62K | 623.80K | 621.42K | 601.53K |
Cash flow statement
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -11.70M | -11.70M | -3.58M | -4.30M | -5.87M | -7.45M |
| Depreciation & Amortization | 404.54K | 404.54K | 392.74K | 745.59K | 769.69K | 604.40K |
| Loss (Gain) From Sale of Assets | 1.42K | |||||
| Stock-Based Compensation | 3.23M | 3.23M | 244.81K | 449.31K | 922.62K | 2.76M |
| Other Operating Activities | -22.52K | -22.52K | -185.77K | -309.38K | -276.60K | -159.34K |
| Change in Other Net Operating Assets | 398.81K | 398.81K | 18.86K | -585.37K | -508.94K | -1.02M |
| Operating Cash Flow | -7.70M | -7.70M | -3.11M | -4.00M | -4.96M | -5.27M |
| Capital Expenditures | -152.69K | -5.38K | -27.39K | -780.88K | ||
| Sale of Property, Plant & Equipment | 970.00 | |||||
| Investment in Securities | 2.50M | 2.50M | 2.84M | 5.25M | 85.40K | -10.00M |
| Investing Cash Flow | 2.50M | 2.50M | 2.69M | 5.24M | 58.98K | -10.78M |
| Short-Term Debt Repaid | -431.97K | |||||
| Total Debt Repaid | -431.97K | |||||
| Net Debt Issued (Repaid) | -431.97K | |||||
| Issuance of Common Stock | 18.72M | 18.72M | 22.67M | |||
| Repurchase of Common Stock | -1.78M | -1.78M | ||||
| Other Financing Activities | 102.28K | 134.91K | 164.00K | |||
| Financing Cash Flow | 16.95M | 16.95M | 102.28K | 134.91K | 22.41M | |
| Foreign Exchange Rate Adjustments | 18.91K | 18.91K | -114.76K | 53.22K | -83.14K | |
| Net Cash Flow | 11.77M | 11.77M | -542.12K | 1.40M | -4.85M | 6.36M |
| Free Cash Flow | -7.70M | -7.70M | -3.27M | -4.01M | -4.99M | -6.05M |
| Free Cash Flow Per Share | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Levered Free Cash Flow | -2.99M | -2.99M | -1.51M | -1.90M | -2.28M | -2.69M |
| Unlevered Free Cash Flow | -2.99M | -2.99M | -1.51M | -1.90M | -2.28M | -2.69M |
| Change in Working Capital | 398.81K | 398.81K | 18.86K | -585.37K | -508.94K | -1.02M |
Ratios
Fiscal year July - June; amounts in USD.
| TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 3.33B | 3.02B | 8.43B | 43.72M | 299.82M | 450.31M |
| Enterprise Value | 3.31B | 3.02B | 8.42B | 38.92M | 284.19M | 451.67M |
| Last Close Price | 6.71 | 6.09 | 17.04 | 0.09 | 0.61 | 0.91 |
| PB Ratio | 249.26 | 226.04 | 1,733.67 | 5.32 | 25.01 | 26.36 |
| P/TBV Ratio | 249.25 | 226.04 | 1,733.67 | 5.32 | 24.92 | 26.39 |
| Debt / Equity Ratio | 0.02 | 0.02 | 0.11 | 0.01 | 0.04 | 0.04 |
| Net Debt / Equity Ratio | -1.04 | -1.04 | -0.90 | -0.96 | -0.93 | -0.92 |
| Net Debt / EBITDA Ratio | 1.19 | 1.19 | 1.18 | 1.78 | 1.86 | 2.10 |
| Net Debt / FCF Ratio | 1.81 | 1.81 | 1.33 | 1.97 | 2.23 | 2.59 |
| Quick Ratio | 10.75 | 10.75 | 7.38 | 41.13 | 19.05 | 28.41 |
| Current Ratio | 10.77 | 10.77 | 7.39 | 41.92 | 19.15 | 28.46 |
| Return on Equity (ROE) | -128.53% | -128.53% | -54.81% | -43.18% | -41.71% | -116.10% |
| Return on Assets (ROA) | -71.54% | -71.54% | -33.20% | -28.11% | -25.59% | -51.87% |
| Return on Capital Employed (ROCE) | -87.40% | -87.40% | -74.00% | -57.50% | -52.20% | -43.70% |
| Earnings Yield | -0.35% | -0.39% | -0.04% | -9.84% | -1.96% | -1.65% |
| FCF Yield | -0.23% | -0.26% | -0.04% | -9.16% | -1.66% | -1.34% |
| Buyback Yield / Dilution | -0.02% | -0.02% | -1.62% | -28.06% |